R&D Heard on the pipeline: R&D in the pharma industry In the fast-paced world of healthcare, it can take a lot of work to keep up-to-date with the numerous innovations, trends, and opinions that emerge each year.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.